



uterine balloon tamponade (UBT)

*A mother is the whole world to a child.
Help us save that world.*

Saving mothers¹ from untimely death due to postpartum hemorrhage.



Ellavi UBT supports the United Nations Sustainable Development Goal #3: To reduce, by the year 2030, the global maternal mortality ratio to less than 70 per 100,000 live births (currently it is around 216 deaths per 100,000 live births).²

annual need, by the numbers



postpartum hemorrhage³



deaths from postpartum hemorrhage⁴



ineffective uterotonic drugs (drug interventions)⁵



hysterectomies could be averted in one year in sub-Saharan Africa alone⁶

ellavi ubt: a safe & effective solution


DEPLOYS QUICKLY

Ellavi UBT is pre-assembled, fills in under one minute, and acts swiftly to stop bleeding. It is easy to use and, once trained, any maternal health care provider should be able to insert it.




FREE-FLOW SYSTEM

Water moves freely between the balloon and the bag. As soon as the uterus regains its ability to contract, the water is pushed back towards the bag. This provides a visual indication of improved uterine contractility and facilitates faster balloon removal.



VERTICAL PRESSURE

Simply lifting the bag allows water to fill the balloon. Adjusting the vertical height of the bag controls pressure between the balloon and the uterus. This pressure needs to be slightly higher than the blood pressure in the uterus to stop bleeding.



cost-effective & ready to make an impact

Ellavi UBT is a regulated device (CE-marked)



1/20th the cost of expensive UBTs



Costs less than \$10USD



Clinical trial shows Ellavi UBT is effective and safe for use.



the sinapi difference

- + Sinapi solutions have been researched and developed for over 15 years.
- + Launched four innovative product ranges successfully with an International clientele.
- + Made in Africa, for Africa
- + Sinapi designs and manufactures high quality, affordable medical devices that have a life-saving impact.

SINAPI
biomedical

tel: +27 21 887 5260

email: sales@sinapibiomedical.com

citations

¹ Life Saving Impact: 169,000 by 2030: Norad, Bill & Melinda Gates Foundation, United States Agency for International Development, PATH. The IC2030 Report. Reimagining global health: 30 high-impact innovations to save lives. Seattle: PATH; 2015. Available at <http://ic2030.org/wp-content/uploads/2015/07/ic2030-report-2015.pdf>.

² United Nations goal 3:Sustainable Development Knowledge Platform 2016: Available at <https://sustainabledevelopment.un.org/sdg3>. Accessed August 24, 2017.

³ AbouZahr C. Global burden of maternal death and disability. Br Med Bull. 2003;67:1–11

⁴ World Health Organization. WHO maternal mortality fact sheet N°348 [Internet]. Geneva: WHO; 2015 [updated November 2015; cited 20 January 2016]. Available from: <http://www.who.int/mediacentre/factsheets/fs348/en/>. World Health Organization, World Bank, UNICEF, United Nations Population Fund. Trends in maternal mortality: 1990 to 2008. Geneva: World Health Organization; 2010.

⁵ Estimated 800,000 annual cases where uterotonics are ineffective (sub-Saharan Africa 500,000 and India 350,000). Herrick T, Mvundura M, Abu-Haydar E. (Running title) Modeling potential health impact of a low-cost UBT on maternal mortality and morbidity in sub-Saharan Africa. April 2016. (Unpublished)

⁶ Norad, Bill & Melinda Gates Foundation, United States Agency for International Development, PATH. The IC2030 Report. Reimagining global health: 30 high-impact innovations to save lives. Seattle: PATH; 2015. Available at <http://ic2030.org/wp-content/uploads/2015/07/ic2030-report-2015.pdf>. And Herrick T, Mvundura M, Burke TF, Abu-Haydar E. A low-cost uterine balloon tamponade for management of postpartum hemorrhage: modeling the potential impact on maternal mortality and morbidity in sub-Saharan Africa. (submitted for publication 2017)